A study published March 18 in Annals of Family Medicine that detailed long-term psychosocial harms of false-positive screening mammograms is compromised by methodological irregularities, underplays the harm of a breast cancer diagnosis and does not address existing strategies used to minimize anxiety, according to statements by the American College of Radiology (ACR), the Society of Breast Imaging (SBI) and breast imaging experts.

Long periods of fasting prior to contrast-enhanced CT, particularly restrictions on fluid intake, vary widely throughout the world, and may ultimately be unnecessary, according to a study published in the May issue of Radiology.

The American Society of Echocardiography (ASE) has developed a mobile device application, iASE, which provides summaries of the societys most popular guidelines.

In response to an erroneous media report, the American College of Radiology (ACR) and the Society of Breast Imaging (SBI) released a joint statement urging patients to disregard trumped up risks of thyroid cancer due to mammography-induced radiation.

November is radiology's month. As radiologists and allied professionals around the world gear up for RSNA, were anticipating a great show. The RSNA 2010 theme—Personalized Medicine—speaks volumes about where radiology is headed. As personalized medicine inches into clinical practice, imaging will take center stage.

According to research presented during the 21st annual scientific sessions of the American Society of Echocardiography (ASE) in San Diego this week, cardiac troponin plasma concentrations and longitudinal strain can predict the development of cardiotoxicity in patients treated with anthracyclines and trastuzumab chemotherapies.

The American Society of Echocardiography (ASE) has issued a consensus statement, supporting the use of contrast agents used to enhance echocardiogram images, and providing a guide for physicians who may be hesitant to use the contrast agents following a 2007 FDA black-box warning. The statement was published in the November issue of Journal of the American Society of Echocardiography.

Two-year data from the SPIRIT III trial, Abbott’s U.S. pivotal trial,demonstrated that its Xience V everolimus-eluting coronary stent systemcontinues to deliver clinically superior benefits compared to BostonScientific’s Taxus paclitaxel-eluting coronary stent system, accordingto a presentation at a late-breaking clinical trials session at EuroPCR2008 in Barcelona, Spain.